Cronos Group (NASDAQ:CRON) Releases Quarterly Earnings Results, Beats Expectations By $0.01 EPS

Cronos Group (NASDAQ:CRON) released its quarterly earnings results on Thursday. The company reported $0.04 EPS for the quarter, beating analysts’ consensus estimates of $0.03 by $0.01, Zacks reports. Cronos Group had a net margin of 39.08% and a return on equity of 4.85%. The company had revenue of $63.45 million for the quarter, compared to analyst estimates of $51.15 million.

Here are the key takeaways from Cronos Group’s conference call:

• Cronos reported record Q3 net revenue, gross profit, and Adjusted EBITDA: revenue rose 75% year over year to $63.5 million, while Adjusted EBITDA reached $17.1 million.
• Canadian brands grew retail sales 41% year over year, versus 1% industry growth, with Spinach gaining share across vapes, flower, and pre-rolls; SOURZ remained the leading edible brand.
• Israel delivered its 11th consecutive quarter of record revenue, up 33%, and revenue in international markets outside Israel increased sevenfold to $13.2 million, led by Germany. Management cautioned that export timing can make international sales uneven from quarter to quarter.
• Cronos completed its CanAdelaar acquisition in the Netherlands, seeing long-term potential in introducing branded products and improving operations. Management expects price compression as supply ramps up and said expansion of the regulated experiment is possible but not something it is relying on.
• The company ended the quarter with $841 million in cash, restricted cash, investments, and deposits, up $14 million from Q2. Management noted possible Q4 softness in Canadian provincial-board purchases and said margins can vary by quarter.

Cronos Group Stock Down 3.0%

Shares of NASDAQ CRON opened at $3.61 on Friday. The firm has a 50-day simple moving average of $3.31 and a 200-day simple moving average of $2.88. Cronos Group has a 52 week low of $2.28 and a 52 week high of $3.91. The stock has a market capitalization of $1.33 billion, a price-to-earnings ratio of 21.24 and a beta of 0.96.

Analyst Upgrades and Downgrades

CRON has been the subject of a number of research reports. Zacks Research upgraded Cronos Group from a “hold” rating to a “strong-buy” rating in a report on Thursday, October 22nd. TD Securities restated a “buy” rating on shares of Cronos Group in a research report on Monday, September 28th. Weiss Ratings raised Cronos Group from a “buy (b-)” rating to a “buy (b)” rating in a report on Thursday, October 8th. Finally, Wall Street Zen raised shares of Cronos Group from a “hold” rating to a “buy” rating in a report on Saturday. One analyst has rated the stock with a Strong Buy rating, three have issued a Buy rating and one has assigned a Hold rating to the company. According to MarketBeat.com, Cronos Group presently has an average rating of “Buy” and a consensus target price of $2.30.

Key Stories Impacting Cronos Group

Here are the key news stories impacting Cronos Group this week:

• Positive Sentiment: Q3 net revenue rose 73% year over year on an organic, constant-currency basis, with the company reporting record net revenue, gross profit and adjusted EBITDA. Revenue of $63.45 million and earnings of $0.04 per share also exceeded analyst estimates of $51.15 million and $0.03, respectively. Cronos Group Reports 2026 Third Quarter Results
• Positive Sentiment: Growth was broad-based: Cronos posted record Canadian sales, a record quarter in Germany, and its 11th consecutive quarter of record net revenue in Israel. Its Spinach brand retained the top position in Canadian vapes and edibles, while the Canatolar acquisition expands its European reach. Q3 2026 Earnings Call Highlights
• Neutral Sentiment: The company said it reduced its share count, which can support per-share results, though the available reports do not quantify the effect. Cronos Group Reports 2026 Third Quarter Results
• Negative Sentiment: Despite beating estimates, Q3 earnings of $0.04 per share were below the $0.07 reported a year earlier. A separate valuation discussion also notes that the stock’s 93% three-year gain puts more focus on whether current earnings justify its valuation. Cronos Group Stock Looks Hard To Call Following Its 93% Run

About Cronos Group

Cronos Group Inc is a Canadian cannabinoid company focused on developing, producing and commercializing cannabis and cannabis-derived consumer products. The company serves adult-use and medical cannabis markets through a portfolio of brands and sells products such as dried flower, pre-rolls, vaporizers, edibles, oils and other cannabis formats, subject to applicable regulations.

Its brand portfolio has included Spinach, which is positioned primarily in the adult-use cannabis market, as well as Lord Jones and PEACE NATURALS.